Do patients with community-acquired pneumonia benefit from systemic corticosteroids?

BEEM Bottom Line

Why is this study important?

Although systemic corticosteroids (SCS) provide benefit to many patients suffering from pulmonary and other diseases, there is an increased risk of adverse events, especially in the presence of bacterial infections. Pneumonia accounts for 2.2% of emergency department (ED) visits in the United States and results in approximately 7–8 ED visits per 1,000 persons per year. Hence, any benefit from systemic corticosteroids (SCS) to community-acquired pneumonia (CAP) patients without significant adverse effects could have an important impact on healthcare.

Which, if any, threats to validity are most likely to have an impact on the results and how?

Thank you for your interest in the BEEM Journal!

To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.

If you would like a pre-view, click here to view some sample articles

Premium Content Available Through Subscription

BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.

A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.